World’s first dengue vaccine, Dengvaxia, approved for use in Mexico

Dec 11, 2015, 09:19 IST

According to a WHO report published in late 2014, the vaccine had an average rate of effectiveness of about 60.8 percent in protecting against the four strains of dengue.

The Mexican authorities on 9 December 2015 approved the use of the first-ever vaccine against dengue fever, which will be publicly available for the first time.

French manufacturer Sanofi Pasteur declared that the Mexican authorities have granted marketing authorization to Dengvaxia, the vaccine against dengue fever.

Key facts related to Dengvaxia vaccine

Sanofi has requested regulatory approval of Dengvaxia vaccine in 20 countries across Asia and Latin America, but Mexico was the first to green flag it.

The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) approved Dengvaxia for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, 9 to 45 years of age living in endemicareas.

The COFEPRIS approval of Dengvaxia is based on results from an extensive clinical development program involving over 40000 people of different ages, geographic and epidemiological settings, and ethnic and socio-economic backgrounds living in 15 countries.

According to a World Health Organization (WHO) report published in late 2014, the vaccine had an average rate of effectiveness of about 60.8 percent in protecting against the four strains of dengue now circulating.

About Dengue

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus.

Overall, the disease is a potential threat to almost half of the world’s population.

Of the estimated 100 million people infected annually, 500000, mostly children, develop dengue hemorrhagic fever (DHF), a severe form of the disease.

DHF is a leading cause of hospitalization, placing tremendous pressure on strained medical resources and having a heavy economic and societal impact.

About Sanofi

Sanofi is a French multinational pharmaceutical company headquartered in Paris, France.

It was founded in 1973 as subsidiary of Elf Aquitaine.

The company engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market.

Now get latest Current Affairs on mobile, Download # 1  Current Affairs App

Jagranjosh
Jagranjosh

Education Desk

Your career begins here! At Jagranjosh.com, our vision is to enable the youth to make informed life decisions, and our mission is to create credible and actionable content that answers questions or solves problems for India’s share of Next Billion Users. As India’s leading education and career guidance platform, we connect the dots for students, guiding them through every step of their journey—from excelling in school exams, board exams, and entrance tests to securing competitive jobs and building essential skills for their profession. With our deep expertise in exams and education, along with accurate information, expert insights, and interactive tools, we bridge the gap between education and opportunity, empowering students to confidently achieve their goals.

... Read More
Get here latest daily, weekly and monthly Current Affairs and GK in English and Hindi for UPSC, SSC, Banking, Railway, Defence and exams. Download Jagran Josh Current Affairs App.

Take Weekly Tests on app for exam prep and compete with others. Download Current Affairs and GK app

AndroidIOS

Trending

Latest Education News